Association of ß-blocker exposure with outcomes in heart failure differs between african american and white patients

Circulation: Heart Failure

Volumn 5, Issue 2, 2012, Pages 202-208

  Lanfear, David E ^a   Hrobowski, Tara N ^a   Peterson, Edward L ^a   Wells, Karen E ^a   Swadia, Tanmay V ^a   Spertus, John A ^b   Williams, Keoki ^a  

^a HENRY FORD HOSPITAL   (United States)

^b Mid America Heart Institute   (United States)

Author keywords

adrenergic receptor blocker; Heart failure; Hospitalization; Race; Systolic dysfunction

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; CAUCASIAN; DEATH; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEART EJECTION FRACTION; HEART FAILURE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL; TREATMENT OUTCOME; CAUSE OF DEATH; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE COURSE; DRUG EFFECT; ETHNOLOGY; HEART STROKE VOLUME; INCIDENCE; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; RISK FACTOR; TIME; UNITED STATES;

ADRENERGIC BETA-ANTAGONISTS; AFRICAN AMERICANS; AGED; CAUSE OF DEATH; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HOSPITALIZATION; HUMANS; INCIDENCE; MALE; MICHIGAN; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; STROKE VOLUME; TIME FACTORS; TREATMENT OUTCOME;

EID: 84860812562     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.111.965780     Document Type: Article

References (34)

1. American Heart Association. Heart Disease and Stroke Statistics: 2009 Update. Dallas, TX: American Heart Association; 2009.
2. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001-2007.
3. Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353:9-13.
4. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, DeMets DL. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651-1658. (Pubitemid 32479962)
5. Yancy CW. Heart failure therapy in special populations: the same or different? Rev Cardiovasc Med. 2004;5(Suppl 1):S28-S35. (Pubitemid 38811477)
6. Goldstein S, Deedwania P, Gottlieb S, Wikstrand J. Metoprolol CR/XL in black patients with heart failure (from the Metoprolol CR/XL randomized intervention trial in chronic heart failure). Am J Cardiol. 2003;92: 478-480. (Pubitemid 36959893)
7. Yancy CW, Fowler MB, Colucci WS, Gilbert EM, Bristow MR, Cohn JN, Lukas MA, Young ST, Packer M. Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. N Engl J Med. 2001;344:1358-1365. (Pubitemid 32378390)
8. Shekelle PG, Rich MW, Morton SC, Atkinson CS, Tu W, Maglione M, Rhodes S, Barrett M, Fonarow GC, Greenberg B, Heidenreich PA, Knabel T, Konstam MA, Steimle A, Warner Stevenson L. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol. 2003;41:1529-1538. (Pubitemid 36543372)
9. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med. 2001;344:1659-1667.
10. Domanski MJ, Krause-Steinrauf H, Massie BM, Deedwania P, Follmann D, Kovar D, Murray D, Oren R, Rosenberg Y, Young J, Zile M, Eichhorn E. A comparative analysis of the results from 4 trials of beta-blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS. J Card Fail. 2003;9:354-363. (Pubitemid 37351802)
11. Maack C, Bohm M, Vlaskin L, Dabew E, Lorenz K, Schafers HJ, Lohse MJ, Engelhardt S. Partial agonist activity of bucindolol is dependent on the activation state of the human beta1-adrenergic receptor. Circulation. 2003;108:348-353. (Pubitemid 36899028)
12. Andreka P, Aiyar N, Olson LC, Wei JQ, Turner MS, Webster KA, Ohlstein EH, Bishopric NH. Bucindolol displays intrinsic sympathomimetic activity in human myocardium. Circulation. 2002;105: 2429-2434. (Pubitemid 34556397)
13. Pladevall M, Williams LK, Potts LA, Divine G, Xi H, Lafata JE. Clinical outcomes and adherence to medications measured by claims data in patients with diabetes. Diabetes Care. 2004;27:2800-2805. (Pubitemid 39565040)
14. Williams LK, Peterson EL, Wells K, Campbell J, Wang M, Chowdhry VK, Walsh M, Enberg R, Lanfear DE, Pladevall M. A cluster-randomized trial to provide clinicians inhaled corticosteroid adherence information for their patients with asthma. J Allergy Clin Immunol. 2010;126:225-231.
15. Lanfear DE, Peterson E, Wells K, Williams LK. Discharge medication status compares poorly with claims-based outpatient medication exposure estimates. Presented at American Heart Association Quality of Care and Outcomes Research, Washington, DC; 2011.
16. Alquasi F, Peterson E, Williams LK, Lanfear DE. Identifying heart failure patients using electronic data resources. Circ Cardiovasc Qual Outcomes. 2009;2:e1-e66.
17. Lee WY, Capra AM, Jensvold NG, Gurwitz JH, Go AS. Gender and risk of adverse outcomes in heart failure. Am J Cardiol. 2004;94:1147-1152. (Pubitemid 39424217)
18. Yang JJ, Burchard EG, Choudhry S, Johnson CC, Ownby DR, Favro D, Chen J, Akana M, Ha C, Kwok PY, Krajenta R, Havstad SL, Joseph CL, Seibold MA, Shriver MD, Williams LK. Differences in allergic sensitization by self-reported race and genetic ancestry. J Allergy Clin Immunol. 2008;122:820-827.
19. Granger BB, Swedberg K, Ekman I, Granger CB, Olofsson B, McMurray JJ, Yusuf S, Michelson EL, Pfeffer MA. Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial. Lancet. 2005;366:2005-2011. (Pubitemid 41773375)
20. Fleiss JL, Levin BA, Paik MC. Statistical Methods for Rates and Proportions. 3rd ed. Hoboken, NJ: J Wiley; 2003.
21. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure: US Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334:1349-1355. (Pubitemid 26152713)
22. Abraham WT, Massie BM, Lukas MA, Lottes SR, Nelson JJ, Fowler MB, Greenberg B, Gilbert EM, Franciosa JA. Tolerability, safety, and efficacy of beta-blockade in black patients with heart failure in the community setting: insights from a large prospective beta-blocker registry. Congest Heart Fail. 2007;13:16-21.
23. Cresci S, Kelly RJ, Cappola TP, Diwan A, Dries D, Kardia SL, Dorn GW II. Clinical and genetic modifiers of long-term survival in heart failure. J Am Coll Cardiol. 2009;54:432-444.
24. Amarasingham R, Moore BJ, Tabak YP, Drazner MH, Clark CA, Zhang S, Reed WG, Swanson TS, Ma Y, Halm EA. An automated model to identify heart failure patients at risk for 30-day readmission or death using electronic medical record data. Med Care. 2010;48:981-988.
25. Bristow MR, Murphy GA, Krause-Steinrauf H, Anderson JL, Carlquist JF, Thaneemit-Chen S, Krishnan V, Abraham WT, Lowes BD, Port JD, Davis GW, Lazzeroni LC, Robertson AD, Lavori PW, Liggett SB. An alpha2C-adrenergic receptor polymorphism alters the norepinephrinelowering effects and therapeutic response of the beta-blocker bucindolol in chronic heart failure. Circ Heart Fail. 2010;3:21-28.
26. Liggett SB, Mialet-Perez J, Thaneemit-Chen S, Weber SA, Greene SM, Hodne D, Nelson B, Morrison J, Domanski MJ, Wagoner LE, Abraham WT, Anderson JL, Carlquist JF, Krause-Steinrauf HJ, Lazzeroni LC, Port JD, Lavori PW, Bristow MR. A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci U S A. 2006;103: 11288-11293. (Pubitemid 44156511)
27. Alqaisi F, Williams LK, Peterson EL, Lanfear DE. Comparing methods for identifying patients with heart failure using electronic data sources. BMC Health Serv Res. 2009;9:237.
28. Habib ZA, Tzogias L, Havstad SL, Wells K, Divine G, Lanfear DE, Tang J, Krajenta R, Pladevall M, Williams LK. Relationship between thiazolidinedione use and cardiovascular outcomes and all-cause mortality among patients with diabetes: a time-updated propensity analysis. Pharmacoepidemiol Drug Saf. 2009;18:437-447.
29. Williams LK, Joseph CL, Peterson EL, Wells K, Wang M, Chowdhry VK, Walsh M, Campbell J, Rand CS, Apter AJ, Lanfear DE, Tunceli K, Pladevall M. Patients with asthma who do not fill their inhaled corticosteroids: a study of primary nonadherence. J Allergy Clin Immunol. 2007;120:1153-1159. (Pubitemid 350029905)
30. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17:2265-2281. (Pubitemid 28466823)
31. Glynn RJ, Schneeweiss S, Sturmer T. Indications for propensity scores and review of their use in pharmacoepidemiology. Basic Clin Pharmacol Toxicol. 2006;98:253-259.
32. Seeger JD, Williams PL, Walker AM. An application of propensity score matching using claims data. Pharmacoepidemiol Drug Saf. 2005;14: 465-476. (Pubitemid 40990742)
33. Joffe MM, Rosenbaum PR. Invited commentary: propensity scores. Am J Epidemiol. 1999;150:327-333. (Pubitemid 29383480)
34. Schulz A, Israel B, Williams D, Parker E, Becker A, James S. Social inequalities, stressors and self reported health status among African American and white women in the Detroit metropolitan area. Soc Sci Medicine. 2000;51:1639-1653.